OCUL

Over the past six months, Ocular Therapeutix's stock (OCUL) experienced several events, including positive Pre-NDA and Type C meetings with the FDA for AXPAXLI in wet AMD, confirming plans for an NDA submission in Q4 2026, which served as significant catalysts. The Q2 2026 financial results reported on August 3, 2026, showed flat total net revenue of $13.5 million compared to the prior year, and a widened net loss of $78.8 million due to increased R&D and selling and marketing expenses for AXPAXLI. The stock gained 12.4% approximately six months ago on news of the first patient enrollment in a Phase III clinical trial for its dry eye disease treatment (OT-211) in China, and in April 2026, the first patient was enrolled in the SOL-X long-term extension trial for AXPAXLI. The company also reported several inducement equity grants to newly hired non-executive employees in September, August, and July 2026. OCUL shares have been highly volatile, declining 14.29% over the past year, 13.8% since the beginning of 2026, and 7.24% over the 30 days leading up to September 24, 2026. On September 23, 2026, the stock fell 6.7% as part of a broader healthcare sector decline. Analysts suggested that a rival's (EyePoint) wet AMD trial miss in mid-August 2026 eased competitive pressure on Ocular's pipeline, providing some support to OCUL's stock.